AtriCure (NASDAQ:ATRC) Price Target Raised to $55.00

AtriCure (NASDAQ:ATRC) had its price target lifted by stock analysts at BTIG Research from $45.00 to $55.00 in a research note issued on Monday, MarketBeat.com reports. The brokerage currently has a “buy” rating on the medical device company’s stock. BTIG Research’s target price points to a potential upside of 12.29% from the stock’s previous close.

A number of other research firms have also recently weighed in on ATRC. UBS Group decreased their price objective on shares of AtriCure from $55.00 to $50.00 and set a “buy” rating for the company in a research report on Tuesday, July 28th. Raymond James Financial set a $52.00 price target on AtriCure in a research note on Tuesday, July 21st. Zacks Research raised AtriCure from a “hold” rating to a “strong-buy” rating in a report on Friday, July 24th. Canaccord Genuity Group lifted their price objective on AtriCure from $53.00 to $55.00 and gave the stock a “buy” rating in a report on Wednesday, May 6th. Finally, Weiss Ratings upgraded AtriCure from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $48.62.

AtriCure Stock Performance

ATRC opened at $48.98 on Monday. The firm’s 50 day moving average is $35.83 and its 200-day moving average is $31.81. AtriCure has a 52-week low of $25.36 and a 52-week high of $49.20. The company has a quick ratio of 3.19, a current ratio of 4.22 and a debt-to-equity ratio of 0.14. The firm has a market capitalization of $2.49 billion, a P/E ratio of 233.25 and a beta of 1.20.

AtriCure (NASDAQ:ATRC) last announced its earnings results on Thursday, July 23rd. The medical device company reported $0.18 earnings per share for the quarter. The business had revenue of $153.60 million during the quarter, compared to the consensus estimate of $151.80 million. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. During the same period in the prior year, the firm earned ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. Analysts expect that AtriCure will post 0.2 EPS for the current fiscal year.

Insider Activity

In other news, Director Maggie Yuen sold 3,500 shares of AtriCure stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $38.42, for a total value of $134,470.00. Following the completion of the transaction, the director owned 14,015 shares in the company, valued at approximately $538,456.30. This trade represents a 19.98% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Justin J. Noznesky sold 6,182 shares of the business’s stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $38.80, for a total value of $239,861.60. Following the completion of the sale, the insider owned 100,219 shares of the company’s stock, valued at $3,888,497.20. This trade represents a 5.81% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 44,246 shares of company stock valued at $1,691,895 over the last three months. Company insiders own 4.00% of the company’s stock.

Hedge Funds Weigh In On AtriCure

A number of hedge funds have recently added to or reduced their stakes in ATRC. AQR Capital Management LLC lifted its position in shares of AtriCure by 1.0% in the 1st quarter. AQR Capital Management LLC now owns 83,685 shares of the medical device company’s stock worth $2,700,000 after buying an additional 837 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of AtriCure by 4.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,146 shares of the medical device company’s stock valued at $908,000 after buying an additional 1,230 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in AtriCure by 1.0% during the first quarter. Goldman Sachs Group Inc. now owns 862,668 shares of the medical device company’s stock worth $27,830,000 after acquiring an additional 8,956 shares during the period. Jane Street Group LLC raised its stake in AtriCure by 658.3% during the first quarter. Jane Street Group LLC now owns 100,853 shares of the medical device company’s stock worth $3,254,000 after acquiring an additional 87,553 shares during the period. Finally, Strs Ohio bought a new position in AtriCure in the first quarter worth about $158,000. Institutional investors and hedge funds own 99.11% of the company’s stock.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.